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YeastProtein aggregation is linked to many pathological conditions, including several neurodegenerative diseases.
The aggregation propensities of proteins are thought to be controlled to a large extent by the physicochem-
ical properties encoded in the primary sequence. We have previously exploited a set of amyloid β peptide
(Aβ42) variants exhibiting a continuous gradient of intrinsic aggregation propensities to demonstrate that
this rule applies in vivo in bacteria. In the present work we have characterized the behavior of these Aβ42
mutants when expressed in yeast. In contrast to bacteria, the intrinsic aggregation propensity is gated by
yeast, in such a way that this property correlates with the formation of intracellular inclusions only above
a speciﬁc aggregation threshold. Proteins displaying solubility levels above this threshold escape the inclu-
sion formation pathway. In addition, the most aggregation-prone variants are selectively cleared by the
yeast quality control degradation machinery. Thus, both inclusion formation and proteolysis target the
same aggregation-prone variants and cooperate to minimize the presence of these potentially dangerous spe-
cies in the cytosol. The demonstration that sorting to these pathways in eukaryotes is strongly inﬂuenced by
protein primary sequence should facilitate the development of rational approaches to predict and hopefully
prevent in vivo protein deposition.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Protein aggregation and the long term cellular persistence of ag-
gregates are pathological hallmarks of a large set of human disorders,
the so-called conformational diseases, such as Alzheimer's (AD),
Huntington's (HD) and Parkinson's (PD) diseases, and diabetes type
II or transmissible spongiform encephalopathies [1,2]. Moreover, pro-
tein deposition is also a common phenomenon during recombinant
expression in simple organisms such as unicellular fungi or bacteria
[3,4]. Interestingly, the aggregates formed in these microorganisms
resemble those involved in the onset of the aforementioned disorders
[5–7], indicating that protein self-assembly into β-sheet enriched
amyloid-like structures is a generic process in direct competition
with native protein folding [8–10], regardless of the considered
host. Indeed, it has been shown that the large majority of polypep-
tides display at least one and often multiple aggregation-proneptide; AD, Alzheimer's disease;
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l rights reserved.regions, usually involved in the formation of the hydrophobic core
[11,12]. As it occurs with folding, the aggregation propensity of pro-
teins represents an essential property of the behavior of polypeptides
encoded in their primary sequences [13–15]. Different bioinformatic
algorithms have exploited this feature to predict protein deposition
and amyloid formation by identifying and quantifying aggregation-
promoting regions within a given sequence [16–19]. Despite their
success in predicting in vitro aggregation, the challenge is asserting
if the predictive power of these programs also applies in a more com-
plex biological context [16]. Addressing this question is not trivial,
since quantitative evaluation of the aggregation propensities of poly-
peptides in vivo is technically complex. In a ﬁrst step toward this di-
rection, we exploited in previous works the competition between
protein folding and aggregation in the bacterial cytosol to approxi-
mate intracellular aggregation rates. Essentially, we generated 19 var-
iants of the Aβ peptide (Aβ42) in which the original Phe residue in
position 19 was substituted by the rest of natural proteinogenic
amino acids. This residue is located in the central hydrophobic cluster
(CHC), a short stretch comprising residues from Leu17 to Ala21 that
controls, to a large extent, the aggregation propensity of the entire se-
quence. The 20 Aβ42 mutants were fused to the green ﬂuorescent
protein (GFP), which acts as a reporter of the aggregation propensity
of the Aβ moiety and were recombinantly expressed in Escherichia
coli. The expression of the different peptide variants in E. coli resulted
in the formation of cytoplasmic amyloid-like inclusion bodies whose
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tant [20,21]. These data constitute the core of AGGRESCAN, a method
implemented in our group to predict protein aggregation propensity
[22,23]. We have shown recently that in this model system the cellu-
lar ﬁtness cost induced by protein deposition is tightly regulated by
the intrinsic properties of the polypeptide chain, linking thus pheno-
type and sequence [24,25].
We have applied here the same approach in yeast to provide a
quantitative assessment of the aggregation properties of proteins
and how they correlate with sequential features in a more complex
eukaryotic background. The budding yeast Saccharomyces cerevisiae
is an excellent model system for the study of human cell biology in
health and disease, since the basic features of eukaryotic cell biology
evolved before the split between yeast and metazoans. This organism
shares with higher eukaryotes numerous fundamental cellular path-
ways involved in neurodegeneration, such as protein quality control,
membrane trafﬁcking, autophagy or oxidative stress [26,27]. On this
regard, humanized yeast models for AD, HD and PD have been suc-
cessfully developed, recapitulating some of the pathological features
associated with these disorders [28–34]. Here we analyzed the aggre-
gation properties of the above mentioned Aβ42 mutants when
expressed in yeast. In contrast to bacteria, where degradative path-
ways did not seem to affect the fate of these polypeptides, in yeast
Aβ42 variants are actively cleared from the cytosol by the yeast pro-
tein quality control machinery. The intrinsic properties of the pep-
tides determine both their in vivo intracellular aggregation and
degradation. This model system should allow to rationalize and pre-
dict the impact of sequential changes in the deposition and degrada-
tion of amyloidogenic polypeptides in eukaryotic environments.
2. Material and methods
2.1. Yeast strain and plasmids
Yeast strain BY4741 (MAT a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) was
transformed with pESC(-Ura) plasmids (Stratagene), encoding for the
Aβ42–GFP fusion protein and the 19 variants differing in the 19th
residue of Aβ42, as previously described [3]. Standard lithium/
polyethylene glycol protocol was used for the transformation and a
glucose selective synthetic complete medium deﬁcient for uracil
(SC-URA) was employed for plasmid selection.
2.2. Protein expression
Yeast cells were grown overnight in glucose SC-URA medium at
30 °C and 100 μL was used to inoculate 5 mL of fresh medium. At an
OD600 of 0.5, cells were changed to a fresh rafﬁnose SC-URA medium.
After 30 min, cells were changed again to a fresh SC-URAmedium con-
taining 2% of galactose as a source of carbon to induce the recombinant
protein expression. After 15 h at 30 °C, cells were harvested, washed in
sterile water and pellets were stored at−80 °C for further analysis.
2.3. Microscopy
Cells were washed three times with sterile PBS and 5 μL was
placed on top of microscopy glass slides and covered with coverslips.
Images were obtained at a 40-fold magniﬁcation using an emission
ﬁlter for GFP under UV light excitation in a Leica ﬂuorescence micro-
scope (Leica DMBR, Heidelberg, Germany).
2.4. Fluorescence measurements
Cell pellets were resuspended in PBS to an OD600 of 1. The emission
spectra of GFP were recorded on a Cary Eclipse Spectroﬂuorometer
(Agilent Technologies, Santa Clara, CA, USA) in the range 500–600 nmwith a data interval of 1 nm and using an excitation wavelength of
488 nm. The experiments were carried out in triplicates.
2.5. Immunoblotting analysis
Cell pellets were resuspended in PBS. 200 μL of each mutant was
prepared to an OD600 of 20 and 5 μL was used for total fraction
Western-blots. For soluble/insoluble fraction analysis, 100 μL was cen-
trifuged and resuspended in the same volume of Y-PER protein extrac-
tion reagent from Thermo Scientiﬁc (supplemented with a protease
inhibitor cocktail tablet) to induce cell lysis. After 20 min of incubation
at room temperature under mild agitation, mixtures were centrifuged
at maximum speed for 30 min. Insoluble fractions were resuspended
in 100 μL of PBS containing a protease inhibitor cocktail tablet and
used forWestern-blot analysis, togetherwith 100 μL of the soluble frac-
tion. 5 μL of each sample was loaded in a 14% SDS-PAGE and blotted
onto a PVDF membrane. Immunodetection was performed using
β-amyloid antibody 6E10 from Covance and membranes were devel-
oped with the ECL method. Densitometries were performed using
ImageJ software. The experiments were carried out in triplicates.
2.6. Flow cytometry analysis
Cells expressing Aβ42wt–GFP and Aβ42F19E–GFP were harvested
and washed three times in 0.22 μm ﬁltered PBS. Flow cytometry mea-
surements were performed using a FACSCanto ﬂow cytometer (BD
Biosciences, San Jose, CA, USA) equipped with a 488 nm blue argon
laser. Gated cells (by means of FSC and SSC parameters) were ana-
lyzed for green emission measured on a 530/30 nm BP ﬁlter.
Obtained data were analyzed using BD FACSDiva 4.0 software.
2.7. Cell viability assays
Overnight cultures of Aβ42wt–GFP and Aβ42F19E–GFP grown in
SC-URA medium supplied with glucose (or galactose, for colony-
forming units assay) were washed with sterile water and diluted to an
OD600 of 0.8. The experiments were carried out in triplicates.
For determining the colony-forming units per mL (cfu/mL), 100 μL
of serial dilutions (10−3–10−7) was plated in medium supplied with
glucose and galactose and incubated at 30 °C for 3 days. Only plates
containing between 30 and 300 colonies were monitored.
For spotting assays, 8 μL of serial dilutions (10−1–10−4) was spot-
ted in glucose and galactose plates, subsequently incubated at 30 °C
for 2 days. This experiment was carried out with all Aβ42–GFP
mutants.
For growth curves, overnight cultures diluted in water were used
to inoculate 250 μL of fresh medium containing glucose and galactose
to a ﬁnal OD600 of 0.15 in 96 well plates. Culture growth was moni-
tored overnight at 28 °C in a Victor 3 Plate Reader (Perkin-Elmer,
Inc., Waltham, MA, USA) measuring the OD595 every 15 min.
2.8. Proteolytic degradation analysis
Yeast strains speciﬁcally used in these assays were: BJ5459 (MAT a
ura3-52 trp1 lys2-801 leu2Δ1 his3Δ200 pep4Δ::HIS3 prb1Δ1.6R can1
GAL) [35], and Δerg6 and Δatg1, both in BY4741 background.
In experiments with chemical compounds, the cell wall permeable
yeast strain, Δerg6, transformed with pESC(-Ura) plasmids, was
incubated overnight with galactose SC-URA medium. Prior to drug
application, protein expression was arrested by changing medium
from galactose to glucose supplemented. Incubation with drugs was
performed for 4 h at 30 °C. The chemical compounds and the ﬁnal con-
centrations used in these assays were: phenylmethanesulfonyl ﬂuoride
(PMSF) dissolved in ethanol (EtOH) at 1 mM, rapamycin dissolved in
dimethyl sulfoxide (DMSO) at 100 nM and MG-132 dissolved in
DMSO at 50 μM; all of them from Sigma-Aldrich. EtOH and DMSO
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The experiments were carried out in triplicates.
3. Results
3.1. Prediction of the aggregation propensity of the 20 Aβ42 mutants
The library of 20 Aβ42 mutants used in this study differs only in the
residue in position 19 of the Aβ peptide [20]. This residue is a Phe in the
wild type sequence, is located in the CHC of the peptide and has been
shown to affect the folding, self-assembly, and ﬁbril structure of Aβ
[36,37]. We analyzed the aggregation propensity of these variants
with three different algorithms conceptually unrelated to AGGRESCAN
[22] to obtain an unbiased evaluation of their intrinsic aggregation
properties previous to their experimental characterization in yeast.
We employed: (i) Zyggregator [38], which uses a set of physico-
chemical properties of amino acid residues such as hydrophobicity,
charge, and the propensity to adoptα-helical or β-structural conforma-
tions. (ii) FoldAmyloid [39], which exploits the amino acid expected
packing density and their propensity to establish hydrogen bonds and
(iii) TANGO [40], which is based on the tendency of a sequence to
form β-sheets that will remain buried in the structure of an amyloid.
The aggregation properties predicted by these algorithms, as well as
AGGRESCAN, for the 20 Aβ42 mutants were normalized and they are
compared in Fig. 1. All predictors converge on ascribing the higher pro-
pensity values to Aβ42 variants displaying aromatic and hydrophobic
residues (Ile, Leu, Met, Phe, Val, Trp and Tyr) in position 19.
3.2. Formation of aggregated foci by Aβ42–GFP mutants in the yeast
cytoplasm
Following the same strategy that we used previously in bacteria, the
20 Aβ42mutants were fused to GFP and the resulting fusions (Aβ–GFP)
were expressed individually in the BY4741 yeast strain. We placed
Aβ–GFP under control of the tightly regulated galactose-inducible
GAL1 promoter to allow, rapid, strong and synchronous induction of
protein expression in all cells. After 15 h of protein expression, GFP
ﬂuorescence was visible in the cytoplasm of all the strains. However,
ﬂuorescent foci were only observable in cells expressing certain mu-
tants, while the rest of the variants presented diffuse GFP ﬂuorescence
throughout the cytoplasm (Fig. 2A). We monitored and quantiﬁed the
presence of foci in 1000 yeast cells for each of the 20 Aβ–GFP variants
(Fig. 2B). Ile, Phe, Tyr, Leu, Met, Trp and Val mutants displayed the
higher proportion of cells containing one or more foci in their cyto-
plasm, followed by Cys, Ala and, to a lower extent, Thr. The rest of var-
iants did not exhibit any detectable Aβ–GFP foci, which contrasts withFig. 1. Comparison of the predicted aggregation propensities of the 20 Aβ42 mutants.
Bar graph representing the aggregation propensities obtained by means of four
bioinformatic algorithms: AGGRESCAN (http://bioinf.uab.es/aggrescan/), Zyggregator
(http://www-vendruscolo.ch.cam.ac.uk/zyggregator.php), FoldAmyloid (http://bioinfo.
protres.ru/fold-amyloid/oga.cgi) and TANGO (http://tango.crg.es/). Values have beennor-
malized for each predictor.mutants like Ile or Phe, where more than 60% of the cells contained vis-
ible aggregates (Fig. 2B). According to the predictions in the previous
section, the mutants resulting in the formation of foci in the yeast cyto-
plasm correspond to those exhibiting a high intrinsic aggregation pro-
pensity. We explored if for those mutants there exists any correlation
between the number of cells displaying visible aggregates and the pre-
viously calculated relative aggregation rates in the bacterial cytosol
(Fig. 2C). A striking correlation between these two parameters was ob-
served (R = 0.95, p b 0.00005), suggesting that the formation of pro-
tein inclusions occurs under similar constraints in bacteria and yeast
cytosols. The data also imply the presence of an aggregation threshold
below which no foci are formed. The residues leading to the formation
of foci correspond precisely with the 10more aggregation-prone amino
acids in the AGGRESCAN scale, in such a way that mutants with resi-
dues whose intrinsic aggregation propensities are below that of Thr
do not result in any foci formation. Fitting the data with the other ag-
gregation propensity scales resulted in lower correlations (Fig. S1), in-
dicating that the aggregation propensities in yeast, in terms of foci
formation, essentially recapitulate those observed in bacteria.
In order to test if the formation of foci was associatedwith a cytotox-
ic effect, we performed spotting assays for the 20 different mutants in
the presence of glucose (repressing conditions) and galactose (inducing
conditions). The data for selected mutants displaying increasing aggre-
gation propensity are shown in Fig. 2D and the complete dataset in
Fig. S2. No signiﬁcant differences between mutants could be observed.
These results are in good agreementwith previous data obtained for fu-
sions of Aβ42 variants displaying different aggregation propensities in
frame with GFP [29] or with the functional domain of Sup35 [41]. We
also monitored the growth kinetics of Phe and Glu mutants, as repre-
sentative of inclusion-forming and inclusion-free variants, respectively,
under repressing and inducing conditions. As expected, yeast growth in
glucose-containing medium was faster than in the presence of galac-
tose, however we could not observe signiﬁcant differences in growth
rates between mutants in any of the two conditions (Fig. S3). The data
conﬁrm that the different variants do not exhibit differential cytotoxic-
ity and are consistent with previous evidences showing that Aβ42
(expressed alone or stabilized by the GFP tag) produced in the cyto-
plasm does not signiﬁcantly impair yeast growth [29].
3.3. Solubility of Aβ42–GFP mutants in the yeast cytoplasm
In order to further characterize the aggregation properties of the dif-
ferent variants, yeast cells were lysed and the resulting soluble and in-
soluble fractions were analyzed by immunoblotting (Fig. 3A). Only the
fusion proteins were immunoreactive to 6E10, an Aβ-speciﬁc antibody.
Quantiﬁcation of the bands corresponding to soluble and insoluble pro-
tein showed that, despite the presence of diffuse ﬂuorescence in the cy-
tosol and the absence of observable foci in many mutants, Aβ–GFP was
in most cases mainly located in the insoluble fraction (Fig. 3B), a prop-
erty that was independent of the system used for cell lysis and not
caused by partial fractionation, since the endogenous yeast cyclin Clb2
and a recombinantly expressed GFP used as controls were localized ex-
clusively in the soluble fraction (data not shown). This result is consis-
tent with previous data in a similar yeast model, where Aβ42 was
fused at the GFP C-terminus and in which both the wild type, forming
cytoplasmic foci, and a double mutant Phe19Ser/Leu34Pro, displaying
diffuseﬂuorescence, were found in the insoluble fraction [42]. However,
in our conditions, the presence of soluble Aβ42–GFP was also observ-
able for many of themutants. This is in contrast to what was previously
observed in E. coli, where, independent of the considered mutant, N95%
of the protein was located in the insoluble fraction. To compare the sol-
ubility of the different variants in yeast, we normalized the fraction of
insoluble protein relative to the sum of soluble and insoluble protein
for each mutant (Fig. 3C). Consistent with their high intrinsic aggrega-
tion propensities, Phe, Trp, Ile and Tyr variants were almost exclusively
located in the insoluble fractions while for polar residues like Glu, Asn
Fig. 2. Expression of the Aβ42–GFP mutants in the intracellular space of S. cerevisiae. (A) Microscopy images of yeast cells expressing Aβ42–GFP variants for 15 h under UV light.
Fluorescence is present either as small foci (red arrows) or diffused in the cytoplasm of the cells. Scale bar represents 10 μm. (B) Graph bar representing the percentage of cells
containing ﬂuorescent foci for each mutant. Values were obtained by monitoring the number of cells with intracellular aggregates among ~1000 cells from two different cultures
for each mutant. (C) Correlation between the percentage of cells containing visible intracellular aggregation foci and the intrinsic aggregation propensity predicted by AGGRESCAN.
(D) Spotting assays in the presence of glucose and galactose (protein induction conditions) corresponding to 5 mutants expressing representative examples of Aβ42–GFP variants
with different aggregation propensities.
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plot of the percentage of soluble protein present in eachmutant relative
to its AGGRESCAN predicted aggregation propensity renders a signiﬁ-
cant correlation (R = 0.81, p b 0.00002) suggesting that intrinsic prop-
erties are important determinants of the in vivo solubility of the
mutants in the cytosol (Fig. 3C).
3.4. Fluorescence levels of Aβ42–GFP mutants in the yeast cytoplasm
In our protein fusions, the GFPmoiety acts as a reporter of the aggre-
gation state of Aβ42 [43]; thus the total ﬂuorescence of intact cells was
expected to reﬂect aggregation propensities, as it occurs in bacteria [20].
Fluorescence emission curves were collected for cells expressing each
Aβ–GFP variant (representative examples are shown in Fig. 3D) and
the relative intensity at the GFP emission maximum (510 nm) was
measured (Fig. 3E). Again the aromatic residues Trp, Phe and Tyr
displayed the lowest ﬂuorescence levels and the polar residues Glu,
Gln and Asn the highest, in such a way that the ﬂuorescence emitted
by cells expressing the Glu variant was nine-fold higher than that emit-
ted by those expressing the Trp variant. This ﬂuorescence dynamic
range between the most and the least ﬂuorescent mutant is more
than two times higher than that observed in E. coli. Fluorescence emis-
sion and predicted aggregation propensity according to AGGRESCANcorrelate signiﬁcantly (R = 0.78 p b 0.00003) (Fig. 3F). However, an
inspection of Fig. 3E and F allows to note deviations from the correlation
for mutants bearing Trp and Phe, that, despite being predicted as
aggregation-prone, behave as outliers, exhibiting lower levels of ﬂuo-
rescence emission than expected, which suggests that in contrast to
bacteria, other factors apart from intrinsic aggregation propensity
might inﬂuence the fate of Aβ–GFP proteins in the more complex
yeast cytosol.
3.5. Protein levels of Aβ42–GFP mutants in the cytoplasm of yeast
From Fig. 4A it is evident that, apart from the distribution between
the soluble and insoluble fraction, the mutants differ in the levels of
total protein present in the cytosol. This is again in contrast with E. coli
data, where protein levels were essentially identical between the differ-
ent mutants [20]. To quantify the cytosolic protein levels we performed
immunoblotting analysis with equal amounts of cells expressing the 20
different variants. As shown in Fig. 4A and B, striking differences be-
tween mutants were observed. Trp and Phe mutants display extremely
low protein levels when comparedwith variants bearing polar residues
like Glu or Gln. The correlation between expression levels and intrinsic
aggregation propensity was signiﬁcant but rather low (R = 0.71,
p b 0.0002). Theoretically, a protein can ﬁt into four different classes
Fig. 3. Solubility and ﬂuorescence of Aβ42–GFP mutants. (A) Western-blots of protein fractions for each mutant. Yeast cells were lysed with a chemical reagent and soluble and insoluble fractions were separated and loaded onto the protein
gels. For each mutant: left and right bands correspond to the soluble (S) and insoluble (I) protein fractions, respectively. (B) Bar graph with the values obtained from the Western-blot quantiﬁcation using ImageJ software. Each bar rep-
resents the ratio between insoluble and total protein levels. (C) Correlation between the relative amount of insoluble protein and the intrinsic aggregation propensity predicted by AGGRESCAN. (D) Examples of GFP ﬂuorescence curves
obtained from cultures after 15 h of expressing Aβ42–GFP. Emission curves of washed entire cells were recorded in a spectroﬂuorometer using an excitation wavelength of 488 nm. (E) Bar graph representing the ﬂuorescence of the 20
mutants expressing Aβ42–GFP obtained from the GFP emission pick at 510 nm. (F) Correlation between the GFP ﬂuorescence and the intrinsic aggregation propensity predicted by AGGRESCAN.
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Fig. 4. Total Aβ42–GFP levels detected by immunoblotting. (A) Western-blots of the
total protein fraction of each mutant. Equal amounts of cultures were loaded onto
the protein gels, as well as a reference band (not shown) to compare both membranes.
(B) Bar graph with the values obtained from the Western-blot quantiﬁcation using
ImageJ software. Each bar represents total AΒ42–GFP level. (C) Dot-plot representing
the spatial distribution of Aβ42–GFP mutants depending on the intrinsic aggregation
propensity predicted by AGGRESCAN and the amount of total Aβ42–GFP. In blue: mu-
tants with low aggregation propensity (AGGRESCAN values b0) presenting high Aβ42–
GFP levels. In red: mutants with high aggregation propensity (AGGRESCAN values N0)
presenting low Aβ42–GFP levels.
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(Fig. 4C). Interestingly, the Aβ–GFP protein set ﬁts only into two of the
four possible groups: (i) proteins with low aggregation propensity and
high protein levels and (ii) proteins with high aggregation propensity
and lowprotein levels.We did not observe anyprotein in the theoretical
classes having high aggregation propensity and high protein levels or
vice versa, which indicates that these two features are always anti-
correlated in our protein set.
To ensure that the observed differences in protein levels were not
caused by differential plasmid loss between mutants, and thus by dif-
ferences in gene expression, cultures containing the same number of
cells of Glu and Phe mutants were plated in glucose or galactose con-
taining selective media 15 h after induction of protein expression and
the number of resulting colonies quantiﬁed. No signiﬁcant differences
in the number of colonies generated by the two strains under
repressing or inducing conditions were observed (Fig. S4) allowing
to discard plasmid copy variability as a major contributor to the ob-
served differences in protein levels.3.6. Proteolytic clearance of Aβ42–GFP variants in yeast
Due to the often deleterious nature of aggregation-prone proteins,
they are usually targeted to degradation to prevent their accumulation
[44]. The ubiquitin–proteasome and autophagy–lysosome/vacuolar
pathways are the two main routes of protein and organelle clearance
in eukaryotic cells [45–47]. Differential proteolysis of the Aβ–GFP vari-
ants might well account for the observed differences in protein steady
state levels. In yeast, amyloidogenic proteins can be degraded both by
the proteasome and by autophagy/vacuolar systems [48,49]. Thus, we
analyzed the impact of blocking these pathways, either using chemical
compounds or genetically modiﬁed strains, on the levels of both the
high and low aggregating Glu and Phe mutants.
We ﬁrst addressed the role of autophagy by expressing the two
Aβ–GFP fusions in a Δatg1 strain. The ATG1 gene (autophagy-speciﬁc
gene 1) encodes for a serine/threonine kinase involved in autophagy reg-
ulation and essential for induction of the autophagic pathway [50]. After
overnight expression, the amount of total protein was found to increase
for both mutants, compared to parental strains, as revealed by immuno-
blotting (Fig. 5A). To further conﬁrm that the autophagy/vacuolar path-
ways were involved in the degradation of these two proteins, they
were expressed in the BJ5459 strain lacking the PEP4 gene encoding
for the vacuolar protease proteinase A, which initiates the activation of
different vacuolar hydrolases, including aminopeptidase I, carboxypepti-
dase Y and proteinase B [51]. As shown in Fig. 5A, the levels of the two
proteins were higher in the mutant strain than in the parental one.
We used a chemical approach to further conﬁrm the contribution
of the autophagy/vacuolar pathways to the observed steady state pro-
tein levels. In this case, the cell wall permeable Δerg6 mutant yeast
strain was used to facilitate drug uptake and increase the intracellular
concentration of the drugs added to the culture [52]: PMSF and
rapamycin. PMSF is a serine proteinase inhibitor that blocks the activ-
ity of numerous vacuolar proteases [53] without affecting the
proteasome function. Rapamycin is an inhibitor of the Tor2 kinase,
which negatively regulates the autophagic pathway; thus rapamycin
acts as an autophagy-inducing drug [54]. Because these compounds
are known to have pleiotropic effects in yeast cells, protein expression
was arrested prior to pharmacological treatments. Immunoblotting
analysis shows that for both mutants protein levels increase after
PMSF treatment and are reduced after incubation with rapamycin,
compared to the respective controls (Fig. 5B), conﬁrming thus the
role played by autophagy and vacuolar proteases in the degradation
of these protein species.
We addressed the role of the proteasomal machinery in Aβ–GFP
clearance using the potent proteasome inhibitor MG-132 [55] in the
Δerg6 strain background. Immunoblots of MG-132 treated cells after
arresting protein expression showed an increase in the protein levels
of both mutants, when compared to controls (Fig. 5C), indicating that
proteasome-mediated pathway is also involved in the processing of
Aβ–GFP fusions.
Importantly, the changes in protein levels observed after chemical
or genetic modulation of the different proteolytic pathways are not
identical in the two mutants (Fig. 5D). Inhibition of proteolytic activ-
ity always has a higher impact on the levels of the Phe variant, where-
as the induction of autophagy by rapamycin preferentially reduces
the levels of the Glu mutant, likely because those of the Phe variant
are already under autophagy control in normal conditions.
We hypothesized that the higher proteolytic susceptibility of the
Phe mutant should be reﬂected not only in an overall lower protein
levels in the cell population but also in a higher number of cells in
which the protein has been completely degraded and thus ﬂuores-
cence cannot be detected. To test this hypothesis, we compared the
proportion of cells displaying and not displaying ﬂuorescence in the
Phe and Glu variants, as measured using ﬂow cytometry, which allows
to uncouple mean ﬂuorescence emission and the number of cells in
the population contributing to this ﬂuorescence (Fig. 6). In agreement
Fig. 5. Involvement of cellular proteolytic pathways affecting Aβ42–GFP levels in Aβ42–GFPwt (F) and Aβ42F19E–GFP (E) mutant. (A) Western-blots against Aβ42–GFP in the au-
tophagy deﬁcient Δatg1 strain (left) and in the protease deﬁcient strain BJ5459 (right). Expression in BY4741 strain is used as control. (B) Western-blots against Aβ42–GFP in the
wall-permeable strain Δerg6 in the presence of the autophagy enhancer rapamycin dissolved in DMSO (left) and in the presence of the proteases inhibitor PMSF dissolved in EtOH
(right). Treatments with the corresponding solvents are used as controls. (C) Western-blots against Aβ42–GFP in the wall permeable strain Δerg6 in the presence of the proteasome
inhibitor MG-132 dissolved in DMSO, which is used as control treatment. (D) Bar graph representing the variation in Aβ42–GFP levels caused by the genetic or chemical modulation
of proteolytic pathways. Values are obtained from the quantiﬁcation of Western-blots using ImageJ software and correspond to the ratio of protein after modulating the proteolytic
activity and protein in their respective controls. In the case of rapamycin treatment, the inverse of the ratio is represented since this compound reduces the protein levels.
Fig. 6. Flow cytometry detection of cells expressing Aβ42–GFP. Flow cytometry analysis of F (wt) and E mutants (upper and lower series, respectively). Left panels correspond to
forward scatter (FCS) vs. side scatter (SSC) dot-plots showing P1 gate. Middle panels correspond to SSC vs. GFP ﬂuorescence dot-plots showing P2 population of cells expressing
Aβ42–GFP. Right panels correspond to cell frequency histograms for the analysis of cells expressing Aβ42–GFP, delimited in P3 population. P2 and P3 are redundant populations
exhibiting similar percentages.
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cells expressing the Glu mutant was clearly higher than this of cells
expressing the Phe variant. More interestingly, whereas we could de-
tect ﬂuorescence in 68% of Glu expressing cells, only 46% of Phe ex-
pressing cells exhibited ﬂuorescence, suggesting a preferential action
of the cellular proteolytic machinery against variants with high aggre-
gation propensity and contributing to explain the association between
aggregation propensity and protein levels observed in Fig. 4.
4. Discussion
Many late-onset neurodegenerative diseases are caused by
aggregation-prone proteins [56]. Extensive genetic and transgenic
data suggest that many of the mutations causing these proteinopathies
trigger disease by conferring an increasing aggregation propensity to
the affected proteins that results in a toxic gain of function [2]. The ag-
gregation propensities of proteins are thought to be controlled to a
large extent by the physicochemical properties encoded in the primary
sequence [15]. It has been shown that this rule applies in vitro, however
it is not clear that it will also work in vivo, where proteostatic mecha-
nismsmight introduce signiﬁcant bias to this relationship. Thus, it is im-
portant to understand both the intrinsic properties and the pathways
that regulate the fate of harmful aggregation-prone proteins inside
living cells. In an attempt to provide new clues on this process, we
have expressed in the yeast cytosol a library of 20 Aβ–GFP mutants
exhibiting a continuous gradient of intrinsic aggregation propensities,
as predicted by different algorithms (Fig. 1) and previously validated
in vivo in bacteria [20]. The characterization of the aggregative proper-
ties of this protein set provides one of the few available quantitative
data to model protein deposition inside eukaryotic cells.
A ﬁrst important observation is that only half of the mutants
formed detectable aggregated foci when expressed in yeast, indicat-
ing that in our particular experimental conditions it exits a threshold
for intracellular inclusion formation. This contrasts with the data pre-
viously obtained in bacteria, where all the variants aggregated into
inclusion bodies. In our set, the foci formation threshold is located be-
tween Ser and Thr, two polar uncharged residues differing only in a
single methylene group, illustrating the exquisite control that the se-
quence exerts on in vivo aggregation propensities, especially if we
take into account that the complete Aβ–GFP fusion consists of ~300
residues. In this way, if we only consider those variants for which
foci formation could be observed, the correlation between the aggre-
gation rates derived from E. coli experiments and the percentage of
cells displaying inclusions in yeast is strikingly high, in such a way
that the 10 mutants showing this capability match exactly with the
10 variants with the highest AGGRESCAN propensities, suggesting
that, as it happens in bacteria [16], this algorithm constitutes a useful
tool to predict protein aggregation tendencies in eukaryotic cells. The
observed correlation between yeast and bacteria data provides one of
the few experimental evidences that sequential features tune protein
aggregation in a similar manner in different biological contexts, a
concept that we all assume to be true when using aggregation predic-
tors to forecast the impact of genetic mutations in human conforma-
tional disorders.
Although coherent with previous reports [42], it was surprising to
observe that even for thosemutants displayingonly diffuseﬂuorescence,
more than 50% of the recombinant protein was located in the insoluble
fraction. This is consistent with the observation that in eukaryotic back-
grounds, aggregation might be different from inclusion formation [57].
Inclusions refer to abnormal intracellular structures observed micro-
scopically, while the formation of aggregates describes a biochemical
phenomenon. The interchangeable use of the two terms results from
the observation that aggregation-prone proteins linked to conforma-
tional disorders are often found in inclusions under pathological condi-
tions. Our data indicate that in yeast these processes can be in fact
experimentally dissociated. In eukaryotes the formation of inclusions isthought to be an active process involving different cellular components,
includingmicrotubules [58]. Accordingly, in a cellularmodel of HD itwas
shown that microtubule inhibition results in a marked reduction of in-
clusions, despite most of the poly-Q protein remained still aggregated
[57]. However, this reduction of inclusion formation was also associated
with an increase in the steady-state level of soluble protein, an observa-
tion that is coherentwith the fact thatmutants unable to form foci in our
dataset are also those exhibiting the highest levels of soluble protein,
thus linking protein-aggregation propensity and inclusion formation in
yeast, in such away that a certain level of solubility would likely prevent
the proteins to enter the inclusion formation pathway. This is in contrast
to what happens in bacteria, where formation of inclusions seems to de-
pend on passive diffusion [59] and all Aβ–GFP variants, including those
bearing polar residues in position 19, appear to be above the aggregation
threshold; thus they differ in their kinetics of aggregation but not in their
solubility at equilibrium [21].
Despite we ﬁnd signiﬁcant correlations between AGGRESCAN pre-
dicted aggregation propensities and the distribution of the variants in
the soluble and insoluble fractions or their overall ﬂuorescence emis-
sion, we also observe important deviations for certain mutants, which
make both correlations being lower than expected. Speciﬁcally, the
most aggregation-prone mutants tend to behave as outliers, displaying
less soluble protein and ﬂuorescence levels than predicted, which sug-
gests that the fate of these mutants might be under special surveillance
by the protein quality controlmachinery (PQC). The PQC consists ofmo-
lecular chaperones and various proteases that recognize and repair
damaged proteins or, alternatively, remove the aberrant proteins [60].
Although, these protein functions tend to be well conserved across spe-
cies, the repertoire of proteins involved in PQC in bacteria and yeast is
certainly divergent, whichmight contribute to the observed differences
between E. coli and yeast models. The fact that, in contrast to bacteria,
the protein steady levels differ between variants suggests that this is
the case.
As a general trend, in our dataset proteins predicted to be soluble
are present at higher levels than those with higher predicted aggrega-
tion propensity, in such away that the cellular protein levels of the dif-
ferent mutants are anti-correlated with their intrinsic aggregation
tendencies (R = 0.71, p b 0.0002). The aggregation propensity of a
given protein sequence in a deﬁned environment depends on different
physicochemical properties, mainly on its hydrophobicity, secondary
structure and overall change [15]. Zyggregator is an algorithm that
uses a parameterization of these properties to predict aggregation
propensities. The correlation between Zyggregator predictions and
protein levels is however low (R = 0.47, p b 0.02), indicating that
the speciﬁc parameters used to predict in vitro aggregation rates do
not work properly to predict in vivo protein levels, which leads us to
the question of what are the speciﬁc physicochemical properties rec-
ognized by the PQC resulting in different protein steady levels in our
system (Fig. 7). In this context, charge does not seem to be a determi-
nant factor, since Gln and Asn exhibit similar or higher protein levels
than the charged acidic Glu and Asp residues. The secondary structure
propensity of the polypeptide chain does not either seem to play a
major role in PQC recognition, since the correlations of protein levels
with β-sheet [61] (R = 0. 52, p b 0.009) and α-helix [61] (R = 0.24,
p b 0.15) propensities are rather low. This leaves us with hydropho-
bicity, a property known to be recognized by the yeast PQC in other
protein models [62]. We selected hydrophobicity scales composed of
experimentally determined transfer free energies for each individual
amino acid since they include the contributions of the peptide
bonds, an important feature if the protein region is expected to be
unfolded and interacting with the components of the PQC. The corre-
lation coefﬁcients between protein levels and hydrophobicity are
R = 0.65 (p b 0.001) and R = 0.72 (p b 0.0002) for the octanol [63]
and interface [64] scales, respectively (Fig. 7). Thus, considering only
the interface hydrophobicity of the residue at position 19 provides a
predictive power similar to that of AGGRESCAN. In fact, Trp, the
Fig. 7. Correlation between Aβ42–GFP protein levels and amino acid physicochemical properties. Aβ42–GFP total protein levels are plotted against different physiochemical prop-
erties of the residue in the 19th position for each mutant: (A) β-sheet propensity from the Chou & Fasman scale, (B) α-helix propensity from the Chou & Fasman scale, (C) hydro-
phobicity derived from the octanol scale and (D) hydrophobicity derived from the interface scale.
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highest hydrophobicity in this scale.
The PQC degradation system should target misfolded species and
not folded states, which implies that it needs to recognize a feature
that reports selectively on conformational defects present in the
misfolded state. Hydrophobicity fulﬁlls this requirement better than
secondary structure, which is characteristic of folded states, or charge,
which is already exposed to solvent in native conformations. Exposed
hydrophobicity constitutes in most cases a structural abnormality
since hydrophobic residues are buried inside the core, involved in
the formation of protein interfaces or located within membranes
and, therefore, their exposure indicates defects in folding, assembly
or membrane insertion. In our dataset, the mutated residues are
expected to be located in an essentially disordered context and highly
exposed to solvent, mimicking the conditions in a misfolded environ-
ment; thus our data provide strong support for a selective recognition
of hydrophobicity by protein degradation systems. Accordingly, we
show that autophagy/vacuolar pathways preferentially target wild
type Aβ over the Glu mutant, since chemical or genetic inhibition of
these pathways results in a higher relative increase of the protein
levels in the wild type protein, whereas induction of autophagy has
a more severe effect in the Glu variant; likely because under these
speciﬁc conditions it becomes a substrate of the degradation path-
way, whereas in normal conditions it is not. The same type of selectiv-
ity seems to apply for the proteasome mediated degradation of Aβ–
GFP fusions. Interestingly enough, Phe, in the wild type, is the most
hydrophobic residue in the interface scale after Trp, whereas Glu oc-
cupies the last position in this hydrophobicity ranking. The fact that
both AGGRESCAN and hydrophobicity scales correlate similarly with
protein levels suggests that the binding of protein substrates to PQCmight require a degree of exposed hydrophobicity similar to that pro-
moting self-assembly and aggregation of the substrates, allowing in
this way the PQC to target speciﬁcally the degradation of dangerous
insoluble sequences. This view is consistent with the fact that the
binding sites of chaperones and ubiquitin ligases acting as upstream
conformational sorters for degradative pathways are themselves hy-
drophobic [65,66].
Our results demonstrate that autophagy is involved in the clearance
ofwild typeAβ–GFP in yeast and are fully consistentwith those recently
reported for a C-terminal fusion of Aβ to GFP, where induction of
autophagy by the drug latrepirdine resulted in an increased degradation
[42], aswell aswith those obtained for a yeast model ofα-synuclein ag-
gregation [49], overall converging to point out autophagy as a critical
and generic component of the cellular clearance of potentially toxic
aggregation-prone proteins. Proteasomal degradation is also involved
in the processing of Aβ–GFP, however its contribution is moderate and
its activity cannot compensate for the lack of autophagic function since
genetic or chemical inhibition of these pathways results in a much less
efﬁcient protein clearance when compared with wild type cells. In fact,
it has been suggested that once aggregation-prone substrates cannot
be efﬁciently handled by the proteasome, autophagy becomes the de-
fault clearance pathway [67]. Nevertheless, the aim of the present
work is not to provide a detailed description of the pathways involved
in intracellular Aβ–GFP degradation, but rather to demonstrate that
the decision on whether a substrate would become a target or not of
these pathways depends on its intrinsic aggregation/hydrophobicity
propensity. Flow cytometry data indicate that the PQC performs fairly
well in protecting cells from the presence aggregation-prone wild type
Aβ–GFP variant, since less than half of the cells exhibit detectable ﬂuo-
rescence and thus an intact fusion, consistentwith the view that a robust
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higher risk of forming insoluble aggregates. Nevertheless, in agreement
with previous observations [29,41], aggregation-pronemutants forming
intracellular deposits are not more cytotoxic than those displaying dif-
fuse cytosolic ﬂuorescence. This might indicate that moderate amounts
of Aβ–GFP aggregates would be below a threshold for toxicity in yeast,
as previously suggested for α-synuclein [49], or, alternatively, they
might play a cytoprotective role as shown for mammalian aggresomes,
which serve as cytoplasmic recruitment centers to facilitate degradation
of toxic proteins by autophagic pathways [57]. If this latter scenario also
applies in yeast, it would be consistent with our observation that the
most aggregation-prone variants both form inclusions and are preferen-
tially targeted for protein degradation, since these two outcomes would
respond to the same process.
It is clear that a deeper knowledge of the mechanism by which
proteins are targeted for degradation will be important for under-
standing pathologic processes. Our present demonstration that
sorting to these pathways is strongly inﬂuenced by the physicochem-
ical properties of the protein sequence should facilitate the develop-
ment of rational therapeutic approaches for protein conformational
diseases. The potency of these types of strategies is highlighted by
the recent observation that proteins ‘tagged’ with small, synthetic,
non-polar molecules that increase their surface hydrophobicity, a
key property according to our study, are targeted for degradation by
the PQC, allowing thus their selective removal [68].
Supplementary data to this article can be found online at http://
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